$67.86
-0.90(-1.30%)
Mkt Cap $5.6B
$36.19
$86.25
52-Week Range
At a Glance
AI-generatedPTC Therapeutics, Inc.
Revenue breakdown: Product (40.3%), Collaboration And License Revenue (17.4%), Translarna1 (14.7%).
8-K
PTC Therapeutics, Inc. appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director with term expiring at the 2026 annual stockholder meeting. Ms. Chutter, with over 40 years at Morgan Stanley including as Chair of Biotechnology Investment Banking, will receive compensation per the outside director policy including a $50,000 annual retainer and specified equity grants.$5.6B
Market Cap
$1.8B
Revenue
$700M
Net Income
Employees939
Fundamentals
How The Business Makes Money
Revenue by Segment
Product40.3%($4.9B)
Collaboration And License Revenue17.4%($2.1B)
Translarna114.7%($1.8B)
Royalty10.2%($1.2B)
Emflaza10.1%($1.2B)
Sephience1.8%($222M)
Other Products1.8%($211M)
Upstaza And Kebilidi1.5%($185M)
Translarna1.2%($140M)
Collaboration Revenue0.8%($100M)
Manufacturing0.1%($9M)
Revenue by Geography
Non Us46.5%($2.8B)
US35.4%($2.1B)
All Other Countries Other Than Russia Brazil And United States10%($604M)
RU4.8%($292M)
BR3.2%($196M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001070081
ISINUS69366J2006
CUSIP69366J200
Phone908 222 7000
Address100 Corporate Court, Warren, NJ, 07080, US
SEC EDGAR